UPPSALA, Sweden, June 1, 2004 (PRIMEZONE) -- Q-Med today announced that the Company has obtained information that Inamed Corporation has filed a request that the U.S International Trade Commission commence an investigation pursuant to Section 337 of the Tariff Act of 1930 against Q-Med and Medicis Aesthetics, Inc., a wholly-owned subsidiary of Medicis Pharmaceutical Corporation, regarding an allegation of infringement of Inamed's U.S. Patent No. 4,803,075 dated February 7, 1986 by the dermal filler, RESTYLANE(R). The Company has also obtained information that Inamed has filed an infringement action against Q-Med and Medicis in the U.S. District Court for the Southern District of California regarding the same patent. After a preliminary investigation regarding the above-referenced complaints, it is Q-Med's and Medicis' belief that they have meritorious defenses as to the infringement claims and the validity of the Inamed patent.
Queries should be addressed to: Bengt Agerup, President and CEO Ph: +46 (0) 70 974 90 25
Note: Q-Med AB operates under the name of Q-Med Scandinavia, Inc. in the USA.
Q-Med is a rapidly growing and profitable biotechnology/medical device company that develops, produces and markets medical implants. All products are based on the company's patented NASHA technology - Non-Animal Stabilized Hyaluronic Acid. The products covered by the RESTYLANE trademark are used for the filling out of lips and facial wrinkles and for facial contouring and today account for the majority of sales. RESTYLANE is sold in over 70 countries and has been approved in the USA. DUROLANE, Q-Med's product for the treatment of osteoarthritis of the hip and knee joints, has been approved in Europe since May 2001. DEFLUX is a product which has been approved in Europe and the USA for the treatment of vesicoureteral reflux (malformation of the urinary bladder) in children. ZUIDEX for the treatment of stress urinary incontinence in women has been sold in Europe since July 2002. Q-Med today has 480 employees, with approximately 310 at the company's production facility and head office in Uppsala. The Q-Med share is listed on the Attract 40 list of the Stockholm Stock Exchange.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2004/06/01/20040601BIT21300/wkr0006.pdf